Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.

Expert review of hematology - 1 Apr 2017

Chiappella Annalisa, Castellino Alessia, Nicolosi Maura, Santambrogio Elisa, Vitolo Umberto

Abstract excerpt

INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is the most common histotype in non Hodgkin lymphoma, with a peak incidence in the sixth decade. The standard treatment for elderly FIT DLBCL patients is Rituximab-CHOP; in unfit and frail patients, chemotherapy at reduced intensity should be considered. Areas covered: In this article, we will review use of standard therapies and new drugs investigated such as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cell Transformation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Management

Share to Drug Discovery

Share to Geriatric Assessment

Share to Lymphoma, Large B-Cell, Diffuse

Share to Recurrence

Source

Identifiers

PMID: 28290728
DOI: 10.1080/17474086.2017.1305264

Genes

BTK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.PMID 28290728Read ↗

Diffuse large B-cell lymphoma: current standard treatment and future perspectives.Semantic proximity Read ↗

Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma.Semantic proximity Read ↗

Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort studySemantic proximity Read ↗

The treatment of Burkitt lymphoma in adults.Semantic proximity Read ↗

Lymphoma: turning biology into cures.Semantic proximity Read ↗

Real-world Outcomes of Diffuse Large B-cell Lymphoma Treated with frontline R-CHOP(-like) regimens in an Asian Multi-ethnic PopulationSemantic proximity Read ↗

Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.Semantic proximity Read ↗

ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trialSemantic proximity Read ↗

Burkitt lymphoma: bridging the gap between advances in molecular biology and therapySemantic proximity Read ↗

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial.Semantic proximity Read ↗

Mantle cell lymphoma: evolving management strategies.Semantic proximity Read ↗

Mechanisms of chemoresistance in diffuse large B‑cell lymphoma and novel therapeutic strategies (Review).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.